A novel gene, designated PQBP-1, which encodes a 265 residue protein that binds to the polyglutamine tract of the brain-specific transcription factor Brn-2, was identified. PQBP-1, which also interacts with the polyglutamine tract of triplet repeat disease gene products, binds with a higher affinity to an expanded polyglutamine tract. PQBP-1 has several functional domains, including hepta-and di-amino acid repeat sequences rich in polar residues essential for its interaction with the polyglutamine tract, a WWP/WW domain which binds to proline-rich motifs in other proteins, a putative nuclear localization signal sequence and a C 2 domain implicated in Ca 2+ -dependent phospholipid signaling. PQBP-1 is located in the nucleus and inhibits transcriptional activation by Brn-2. Overexpression of PQBP-1 in P19 embryonic carcinoma cells suppresses their growth rate and enhances their susceptibility to various stresses including serum deprivation, retinoic acid treatment and UV irradiation. Northern blot and in situ hybridization analyses revealed that PQBP-1 is a ubiquitous protein and is expressed primarily in neurons throughout the brain, with abundant levels in hippocampus, cerebellar cortex and olfactory bulb. These results suggest that PQBP-1 mediates important cellular functions under physiological and pathological conditions via its interaction with polyglutamine tracts.
INTRODUCTION
The polyglutamine tract has attracted considerable attention in recent years because of its conservation and abnormal expansion in proteins mutated in hereditary neurodegenerative diseases known as triplet repeat disorders. These include Huntington's disease (1), Kennedy's disease (2), dentatorubropallidoluysian atrophy (3-6), Machado-Joseph disease (7) and other spinocerebellar ataxias (8) (9) (10) (11) . In addition to genetic data, CAG repeat expansion itself has been shown to trigger neuronal death in transgenic animal models (12, 13) . Structurally, the polyglutamine tracts encoded by disease-causing genes have been shown by X-ray diffraction studies to form β-sheets and have been hypothesized to function as polar zippers (14) . Recent observations indicate that caspases are involved in the cleavage of some polyglutamine tract-containing proteins (15, 16) and that the resultant fragments aggregate as intranuclear inclusion bodies (17) (18) (19) . In addition, transglutaminase has been suggested to facilitate the aggregation of longer polyglutamine tracts (20) , and its inhibition partially suppresses apoptosis (21) .
To date, several proteins interacting with polyglutamine tractcontaining disease gene products have been cloned, including huntingtin-associated protein (HAP) (22) , huntingtin-interacting protein (HIP) (23) , glyceraldahyde 3-phosphate dehydrogenase (GAPDH) (24) and leucine-rich acidic nuclear protein (LANP) (25) . The relationship among these various interacting proteins is unclear as their function(s) and subcellular localization appear different. Thus, the structural rules governing the molecular interaction between the polyglutamine tract of disease gene products and their associated proteins remain unexplored. Identification of such interacting proteins is essential not only for understanding the pathological aggregation process but also for clarifying the physiological function of the disease gene products.
The polyglutamine tract is also found in numerous transcription-related proteins such as human transcription initiating factor TFIID/TATA-binding protein, glucocorticoid receptor, octamer-binding POU transcription factors and CREB-binding protein (CBP), as determined by computer-assisted homology search (http://www.blast.genome.ad.jp/BLASTPsearch/non-redundant ; GenBank CDS database). In addition, some cell surface proteins, such as Notch, have the same motif. Not surprisingly, the polyglutamine tracts in triplet repeat disease gene products appear structurally identical to those in transcriptional proteins based on antibody recognition (26) . Collectively, these observations suggest that the polyglutamine tract is used as a functional domain in many proteins, especially those implicated in gene regulation.
We recently hypothesized the presence of different cofactors which bind to the polyglutamine tract of POU transcription factors, thus determining their differential actions in neuron-specific gene expression (27, 28) . In the present investigation, we used the polyglutamine tract of the POU domain protein Brn-2 as bait in the yeast two-hybrid screening method and isolated a cDNA encoding a novel protein with unique structural domains. This nuclear protein, which also binds to the polyglutamine tract of triplet repeat disease gene products, modulates transcription as well as cell survival.
RESULTS

Isolation of the polyglutamine tract-binding protein, PQBP-1
The yeast two-hybrid selection method was employed to identify proteins that bind to the polyglutamine tract in the POU transcription factor Brn-2. A cDNA fragment containing 26 CAG repeats and a few additional amino acids at each end was subcloned into the pEG202 bait plasmid. This approach of essentially limiting the bait sequence to the polyglutamine tract has not been applied previously to screen for proteins that bind to triplet repeat disease gene products. Yeast strain EGY48, constitutively expressing bait plasmid and reporter plasmid pSH18-34, was transformed with a human embryonic brain cDNA library constructed in the pJG4-5 prey plasmid. Yeast clones were grown on SD-HWU plates which do not require an interaction between bait and prey, and then replica clones were selected on Leu-plates (SG-HWUL). Colonies with high growth rates were picked and positive clones were selected by galactose-induced transactivation in X-gal + plates (SG-HWU-X-gal) and in SG-HWUL plates. Isolated clones had polar amino acid-rich sequences (29) . Notably, none of the clones obtained from this screen contained a polyglutamine tract, although self-aggregation of polyglutamine is thought to be of pathogenic importance (17) (18) (19) .
One of these clones, designated PQBP-1 [poly-glutamine (Q) tract-binding protein-1], had a long coding sequence with an open reading frame of 265 amino acids (Fig. 1a ) in-frame with the pJG4-5 protein-coding sequence. PQBP-1 was analyzed further because of its abundant expression in brain (Fig. 2) . A BLAST homology search revealed sequences homologous to PQBP-1 in the genome database, but their biological significance has not been reported. Among these sequences, JM26 cDNA (GenBank accession no. AJ005893) is identical to the PQBP-1 sequence and has an in-frame stop codon upstream of the putative first methionine in PQBP-1. This initiator methionine is also preserved in T21D12.3 reported in Caenorhabditis elegans (GenBank accession no. AF016687), which has 43% homology and 31% identity to PQBP-1. In addition, the nucleotide sequence around the first methionine of PQBP-1 is consistent with Kozak's consensus sequences (30) , suggesting that translation starts at this site.
Domain structure of PQBP-1
The deduced amino acid sequence of PQBP-1 has several interesting features (Fig. 1b) . Its N-terminal portion contains a WWP/WW domain in which tryptophan, tyrosine and proline residues are positioned at conserved intervals. This domain has weak homology to the Src homology 3 domain and is known to bind to the proline-rich PY motif (31) . Protein-protein interactions involving the WW domain and the PY motif have been observed widely between Yes and YAP, between formin and FBP, between dystrophin and dystroglycan, as well as others (31) . In its mid-portion, PQBP-1 encodes five tandem repeats of hepta-amino acids consisting mostly of basic and acidic residues. The latter motif is not found in other proteins and thus appears to be specific to PQBP-1. Immediately C-terminal to the hepta-amino acid repeat domain, PQBP-1 encodes diamino acid repeats, composed of arginine (R) alternating with aspartic acid (D) or glutamic acid (E), forming the DR/ER motif. A similar sequence was first found in the RD protein, which is closely related to several nuclear RNA-binding proteins (32) . Interestingly, the transcriptional co-repressor SMRT has the RD repeat motif (33) , and a triplet repeat disease gene product, atrophin 1, has the RE repeat motif (6) . Toward its C-terminal portion, PQBP-1 has a putative nuclear (Fig. 1) . Most proteins having the C 2 domain function in signal transduction or membrane traffic (34) . Analysis of secondary structure using MacVector revealed that PQBP-1 could form α-helices at multiple sites. In particular, the polar amino acid-rich domain, including hepta-and diamino acid repeats, is highly likely to form an α-helix. The PQBP-1 homolog in C.elegans, T21D12.3, also has a conserved WWP domain and a putative nuclear translocation signal. Although T21D12.3 does not have the di-or heptaamino acid repeat sequences, it has a polar amino acid-rich domain in its mid-portion. The strong structural conservation of this protein from nematodes to humans suggests that it has important biological functions.
PQBP-1 expression in brain
Northern blot analysis detected an~1.0 kb message of PQBP-1 expressed ubiquitously at comparable levels among various tissues (Fig. 2a) . In the brain, PQBP-1 mRNA is detected in all regions tested by northern analysis (Fig. 2b) . In situ hybridization confirmed that this message is distributed widely in brain, with relatively high levels in cerebellar cortex, hippocampus and olfactory bulb (Fig. 2c) . Comparison of relative grain counts per cell between various brain regions revealed that the cerebellum has the highest density (38 ± 2.1), followed by hippocampus (31 ± 2.7) and olfactory bulb (25 ± 2.4). All these three regions had a significantly higher number of grains per cell compared with cerebral cortex (13 ± 1.0) (ANOVA, P < 0.0001). Co-staining for PQBP-1 in situ and glial fibrillary acidic protein (GFAP) immunohistochemistry of cerebral cortical sections showed that the PQBP-1 message is present primarily in neurons (Fig. 2d) . In the striatum, several neurons were found to co-express both PQBP-1 and Brn-2 messages, although PQBP-1 appeared to have a wider distribution (Fig. 2e ). These findings suggest that PQBP-1 probably has important function(s) in all tissues, a hypothesis further supported by the fact that this gene is highly conserved from nematodes to mammals. Determination of the relative expression level of PQBP-1 protein in different brain regions awaits the generation of a specific antibody for immunohistochemial analysis.
The polyglutamine tract-binding domain in PQBP-1
The ability of PQBP-1 to bind to Brn-2 was confirmed using immunoprecipitation. P19 cells were co-transfected with Brn-2 and PQBP-1-Myc/His tag fusion protein expression vectors and the cellular proteins were precipitated by anti-Brn-2 antibody (Fig. 3a) . The precipitates were blotted to a membrane, and coprecipitation of the PQBP-1 fusion protein was detected by antiHis antibody. For negative controls, samples from P19 cells transfected with only one of these expression vectors and from Interactions between the two molecules were tested by culturing four independent colonies on SG-HWUL and SG-HWU-X-gal plates for 2 days. (c) Two-hybrid interaction between PQBP-1 and polyglutamine tract from normal (nHD = 23 repeats) and CAG repeat-expanded (dHD = 58 repeats) huntingtin. HD1 included the polyglutamine and polyproline tracts of huntingtin, whereas HD2 includes only the polyglutamine tract. Interactions between the two molecules were tested by culturing four independent colonies on SG-HWUL and SG-HWU-X-gal plates for 2 days. The quantitative liquid β-galactosidase assay in (b) and (c) was performed as described in Materials and Methods. non-transfected P19 cells were analyzed similarly. PQBP-1-His tag fusion protein was detected only in the co-transfected P19 cells (Fig. 3a, lane 2) , suggesting that Brn-2 interacts with PQBP-1 in cells.
To identify the specific domain in PQBP-1 that participates in binding to the polyglutamine tract, the yeast two-hybrid assay was employed. We inserted full-length and truncated PQBP-1 cDNAs into pJG4-5 yeast plasmid and tested their interaction with the Brn-2 polyglutamine tract in pEG202. Transfected yeast cells initially were cultured on SD-HWU plates, and surviving colonies were then picked and tested on SG-HWUL and SG-HWU-X-gal plates. To obviate saturation of growth and of color change, these plates were incubated for 2 days only. Serial deletion of the di-and hepta-amino acid repeats markedly reduced binding in SG-HWUL and SG-HWU-X-gal plates in a stepwise manner, indicating that both of these polar amino acidrich regions are essential for interaction with the polyglutamine tract (Fig. 3b) . Our results also suggest that the WW domain of PQBP-1 is not involved directly in binding to the polyglutamine tract, supporting data from other WW-containing proteins that interact primarily with the polyproline tract of triplet repeat disease gene products (35) .
PQBP-1 binds to triplet repeat gene products
We also tested whether PQBP-1 binds to the polyglutamine tract in triplet repeat disease gene products. A definite interaction was observed between PQBP-1 and the polyglutamine tract of huntingtin (Fig. 3c) . This binding affinity seemed to be stronger with a CAG expanded huntingtin obtained from an affected patient when tested in both SG-HWUL and SG-HWU-X-gal plates (Fig. 3c) . The difference in the binding affinity between normal and expanded huntingtin to PQBP-1 was substantiated further using a quantitative β-galactosidase assay (Fig. 3c) . We also confirmed the interaction of PQBP-1 with the androgen receptor in which polyglutamine tract expansion causes Kennedy's disease (2) (data not shown). These observations are consistent with our finding that PQBP-1 binds directly to the polyglutamine tract.
Subcellular localization of PQBP-1
To confirm the subcellular localization of PQBP-1, we constructed vectors expressing fluorescent fusion proteins of PQBP-1 and EGFP. In NS20Y cells, full-length PQBP-1 fusion protein localized predominantly in the nucleus (Fig. 4a  and b) . On the other hand, truncated PQBP-1 fusion protein lacking the putative NLS sequence from its C-terminus did not show clearly predominant nuclear fluorescent signal ( Fig. 4c  and d) , suggesting that the putative NLS sequence is necessary for efficient translocation to the nucleus. These findings suggest that PQBP-1 is probably a nuclear protein that colocalizes with the transcription factor Brn-2 (Fig. 2e) .
Effect of PQBP-1 on transactivation by Brn-2
The effect of PQBP-1 on Brn-2-induced transcription activation was analyzed because PQBP-1 was isolated by virtue of its binding to the polyglutamine tract of Brn-2 and because it colocalizes with Brn-2 in the nucleus. We previously had found that Brn-2 does not transactivate the human D 1A dopamine receptor gene appreciably in Neuro2A cells (27, 28) . Therefore, to use the same combination of reporter and effector plasmids, we searched for a suitable cell line that does not express either Brn-2 or PQBP-1 and in which transfected Brn-2 induces transcriptional up-regulation. However, northern blot analysis revealed that PQBP-1 is expressed abundantly in many cell lines (data not shown).
We finally chose NS20Y cells in which PQBP-1 expression is not very high and in which Brn-2 transactivates the D 1A gene. Thus, co-transfection experiments using Brn-2 and PQBP-1 expression vectors revealed that PQBP-1 completely and consistently suppresses the ability of Brn-2 to transactivate the D 1A gene (Fig. 5) . This inhibition was observed in the presence of Brn-2 expression vector and not with PQBP-1 alone, suggesting that this property of PQBP-1 is Brn-2 dependent. 
Effects of PQBP-1 overexpression on cell viability
To study the functional properties of PQBP-1 on cell survival, we stably overexpressed PQBP-1 fused to Myc/His tags at its C-terminus in embryonic carcinoma P19 cells. High expression of the PQBP-1 transgene was detected in the transfected cells using anti-His antibody (Fig. 6a) . Compared with the morphology of the parental cell line, PQBP-1-overexpressing cells manifested elongated cell bodies and overextended processes (Fig. 6b) . In addition, transfected cells grew more slowly than parental P19 cells (Fig. 6c ) and their percentage cell death was higher under stressful conditions including serum deprivation, retinoic acid treatment and UV irradiation (Fig. 6d) . These observations implicate PQBP-1 in cell growth and survival processes.
It is also noteworthy that the western blot analysis of stably transfected cells showed a ladder of higher molecular weight bands (Fig. 6a) . This finding might suggest that PQBP-1 is polyubiquitinated in these cells.
DISCUSSION
In this study, we report a novel protein, PQBP-1, that binds to polyglutamine tracts via its polar amino acid-rich domain. PQBP-1 also has a WW domain which could interact with the PY motif, and a C 2 domain which could interact with Ca 2+ ions and phospholipids (31, 34) . These findings suggest that PQBP-1 can transduce cellular signals between proteins with polyglutamine tracts and those with the PY motif, and that this signaling pathway could be modified by calcium and phospholipids. Ultimately, this signaling cascade appears to culminate in regulation of gene transcription, since PQBP-1 is transported from the cytoplasm to the nucleus and affects Brn-2-induced transactivation. This proposed signal-regulated transcriptional control function of PQBP-1 is analogous to the recent finding that the transcription co-factor CBP is regulated by nuclear calcium and the calmodulin-dependent protein kinase pathway, and by cAMP (36) .
The present observations identify a specific protein motif in PQBP-1 that interacts directly with the polyglutamine tract, namely the polar amino acid-rich domain containing heptaand di-amino acid repeats. This finding is based on our strategy to essentially limit the bait sequence to the polyglutamine tract and serially deleting segments of PQBP-1 in the yeast twohybrid screen (Fig. 3b) . The polar amino acid-rich domain of PQBP-1 is predicted to have an α-helical structure with polar amino acids on its surface. This structure could interface with the polar zipper formed by the polyglutamine tract (14) . While the hepta-amino acid repeat motif is specific to PQBP-1, sequences homologous to the DR/ER repeat are found in other proteins, including RD protein (32), the transcription corepressor SMRT (33) and, interestingly, the DRPLA gene product itself (6) . Among proteins reported to bind to triplet repeat disease gene products, a weak homology to the DR/ER motif is found only in the C-terminal region of LANP which interacts with ataxin-1 (25) . Neither of these polar amino acidrich motifs is present in HIP (23), HAP (22) or atrophin-interacting protein (35) . Rather, the latter proteins have the WW domain which interacts with the PY motifs in their respective protein partners (31, 35, 37) . Thus, PQBP-1 is the first molecule shown to bind to the polyglutamine tract directly.
In addition to its effect on transcription, overexpressed PQBP-1 suppresses the growth of cells and increases their susceptibility to various stresses. Whether its effects on cell growth and survival are directly related to its role in transcription remains to be determined. Although PQBP-1 binds to the polyglutamine tract in transcription factors and triplet repeat disease gene products, it could also interact with other classes of proteins. PQBP-1 has multiple protein modules including WW and C 2 domains known to function in signal transduction. Stable expression in embryonic stem cells induces morphological changes and affects cell survival. Furthermore, this gene is highly conserved during evolution and is widely expressed in various tissues. Thus, it is quite likely that PQBP-1 transduces signals important for basic cellular functions.
The above observations taken collectively could also implicate PQBP-1 in certain neurodegenerative processes. Its higher binding affinity for the expanded polyglutamine tract, its effects on cell survival, its relatively high expression in the cerebellum as well as its nuclear localization suggest that PQBP-1 could have a role in the pathogenesis of some triplet repeat disorders in which polyglutamine tracts deposit in the nucleus of neurons.
MATERIALS AND METHODS
Yeast two-hybrid cDNA cloning
Two-hybrid cDNA cloning was performed according to the method of Gyuris et al. (38) . To construct the bait plasmid, a DNA fragment corresponding to the polyglutamine tract of Brn-2 was amplified by PCR from pCMVBrn2 (39) and subcloned between the EcoRI and XhoI sites of pEG202 in the correct frame. The resultant fragment encoded amino acids 122-154 of the murine Brn-2 which, in addition to 26 glutamines, includes Gly-Ala-Leu and Arg-Pro-Pro at the 5' and 3' ends, respectively, and a His at the fourth position in the polyglutamine tract (40) . After confirming that the bait plasmid itself could not activate transcription from the GAL1-GAL10 promoter in the reporter plasmid pSH18-34, we screened a human embryonic brain cDNA library constructed in pJG4-5. Approximately 2 × 10 6 colonies were screened on plates with synthetic medium lacking histidine, tryptophan and uracil. Positive clones were checked in four types of second plate as described (38) . pJG4-5 plasmids were recovered from the final positive yeast clones and their inserts were sequenced using an automated sequencer. To obtain the entire sequence of inserts, they were subcloned in pBS-SK (Stratagene, La Jolla, CA), and the Kilo-Deletion kit for DNA sequencing (Takara Pharmaceuticals, Kusatsu, Japan) was used. Secondary structure was analyzed with MacVector (International Biotechnologies, New Haven, CT).
Construction of plasmids containing huntingtin
Genomic DNA samples were prepared from lymphocytes (41) and used for amplification of the CAG repeat portion of the huntingtin gene. Two fragments of different lengths were amplified from a normal individual (nHD = 23 CAG repeats) and from a patient with Huntington's disease (dHD = 58 CAG repeats). Genomic PCR was used to amplify fragments nHD1 and dHD1 containing both the polyglutamine and polyproline tracts of the huntingtin gene using primers F: AAAGAATTC-GAGTCCCTCAAGTCCTT and R1: AAACTCGAGCGGCT-GAGGAAGCTGAGGA. To amplify only the polyglutamine tract, fragments nHD2 and dHD2 were generated using primers F and R2: AAACTCGAGCGCGGCGGTGGCGGCTGTT. The resultant PCR products were inserted between the EcoRI and XhoI sites of pEG202 and used for yeast two-hybrid assays. For quantitative analysis of the interaction among these yeast fusion proteins, β-galactosidase assay was performed according to a standard protocol (42) .
Myc/His tag vectors of PQBP-1
Full-length and deleted PQBP-1 cDNA fragments were subcloned between the EcoRI and BamHI sites of pcDNA3.1-Myc-His A (Invitrogen, Groningen, The Netherlands). Sequencing verified that the resultant plasmids correctly encode the Myc/His tag in the C-terminus of PQBP-1.
Immunoprecipitation
P19 cells were transfected with pCMVBrn-2 (39), with the PQBP-1-Myc/His tag fusion protein expression vector described above, or with both vectors. After 36 h, 1 × 10 7 cells were collected, incubated at 4°C for 10 min in 1 ml of TNE lysis buffer [10 mM Tris-HCl, pH 7.8, 1% NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 10 µg/ml aprotinin] and disrupted by repeated aspiration through a 21 gauge needle. Cellular debris were removed by centrifugation at 10 000 g for 10 min. The supernatant was recovered and pre-incubated with protein Gagarose (Oncogene Science, Uniondale, NY) for 1 h at 4°C. Subsequently, 2 µl of anti-Brn-2 polyclonal antibody, Brn-2 (C-20) (Santa-Cruz Biotechnology, Santa Cruz, CA), was added to the soup, incubated for 1 h at 4°C and precipitated with protein G-agarose (Oncogene Science). The beads were washed extensively with TNE buffer four times. Precipitates were recovered with sample buffer, separated by 15% SDS-PAGE, blotted to Hybond-ECL membrane (Amersham, Little Chalfont, UK), incubated with anti-His (C-term) antibody (Invitrogen) and detected with the ECL western blotting analysis system (Amersham).
In situ hybridization and immunohistochemistry
Riboprobes for PQBP-1 (1 kb) and Brn-2 (0.4 kb) were constructed from cDNA clones in pBluescript II (SK+). Mouse brains were sectioned at 12 µm thickness, sections were thaw mounted on silanized slides and in situ hybridization was performed using a previously described procedure (43, 44) . Probes were labeled with [ 35 S]UTP by in vitro transcription using MAXIscript (Ambion, Austin, TX) and 1 × 10 6 c.p.m. was applied to each slide. To detect co-expression of PQBP-1 and Brn-2, mouse brains were sectioned at 4 µm thickness and adjacent sections were processed for in situ hybridization for the two different riboprobes. Hybridized slides were dipped in nuclear emulsion (Eastman Kodak, Rochester, NY) to detect cellular expression. Silver grains on PQBP-1 hybridized sec- tions were counted from each of 12 randomly selected cells in different brain regions using 1000× magnification photomicrographs. These grain counts were analyzed statistically using factorial ANOVA followed by Bonferroni post hoc test. Hematoxylin and eosin (H&E) staining was done according to standard procedures. For immunohistochemical detection of glial cells, a fluorescent GFAP antibody (Sigma, St Louis, MO) was used. Prior to in situ hybridization, mouse brain sections were fixed in 4% paraformaldehyde for 10 min. After three washes in phosphate-buffered saline (PBS), sections were immersed in blocking solution [1% bovine serum albumin, 0.6% Triton X-100, PBS] for 30 min followed by washing in PBS again. Slices were then incubated in primary antibody (1:1000) overnight at 4°C and processed for in situ hybridization.
Fluorescent fusion protein expression vector
To construct PQBP-1-EGFP fusion proteins in the correct frame, full-length and truncated PQBP-1 cDNAs were amplified by PCR with PQBP-1 cDNA in pJG4-5 as template using the following primers: for full-length PQBP-1, F: AAAGAAT-TCCTATGCCGCTGCCCGTTG and R: AAAGGATCCT- GCTGCTTGGTTCGGGA; for truncated PQBP-1 lacking the NLS from its C-terminus, F and R-t: AAAGGATCCTCTTT-GCCCTCTTCCCG. The amplified cDNA fragments were digested with EcoRI and BamHI and subcloned between the corresponding sites of pEGFP-N1 (Clontech, Palo Alto, CA). The resultant fusion proteins have PQBP-1 amino acid sequences upstream of EGFP. After verifying the sequence, these expression vectors were used to transfect NS20Y cells according to the calcium phosphate precipitation method (41) to express the fusion proteins transiently. Cells were visualized with a fluorescent microscope (Olympus IX-FLA) 36 h after transfection.
CAT assay
To construct the PQBP-1 expression vector pCMVPQBP-1, full-length PQBP-1 cDNA was cut out from pJG4-5 using EcoRI and XhoI and subcloned between the EcoRI and SalI sites of pCI-neo mammalian expression vector (Promega, Madison, WI). PCAT-HD1G-D (45) was used as the reporter plasmid, pCMVBrn2 (39) or pBluescriptSK+ were used as the first effector plasmid, and pCMVPQBP-1 or pBluescriptSK+ were used as the second effector plasmid. NS20Y cells were co-transfected with 10 µg of each of the three plasmids using the calcium phosphate precipitation method, and CAT assay was carried out as described previously (28, 41) .
Cell survival assays
A total of 1 × 10 5 cells was plated in cell culture grade six-well dishes and incubated in α-medium without fetal bovine serum (FBS), in the presence of 0.1 µM all-trans retinoic acid, or in the presence of 10% FBS after irradiation with 1200 J/cm UV 2 . After 24 and 48 h, total cell number and percentage cell death were quantitated using trypan blue staining.
